MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/hep.31841

Медицинская библиотека · Hepatology (Baltimore, Md.) · 2021

Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study.

Jonas Maureen M, Rhee Susan, Kelly Deirdre A, Del Valle-Segarra Antonio, Feiterna-Sperling Cornelia, Gilmour Susan, Gonzalez-Peralta Regino P, Hierro Loreto, Leung Daniel H, Ling Simon C, Lobzin Yuri, Lobritto Steven, Mizuochi Tatsuki, Narkewicz Michael R, Sabharwal Vishakha, Wen Jessica, Kei Lon Hoi, Marcinak John, Topp Andrew, Tripathi Rakesh, Sokal Etienne

Клиническое исследование II фазыКлиническое исследование III фазыСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND AND AIMS: Glecaprevir/pibrentasvir (GLE/PIB) has shown high efficacy and safety in chronic HCV-infected adults and adolescents; data in children were limited. DORA part 2 is a phase 2/3, nonrandomized, open-label study evaluating the pharmacokinetics, efficacy, and safety of a pediatric formulation of GLE and PIB in children ages 3 to < 12 years.

APPROACH AND

RESULTS

Children with chronic HCV infection, genotype 1-6, with or without compensated cirrhosis, were divided into three cohorts by age-cohort 2 (9 to < 12 years), cohort 3 (6 to < 9 years), and cohort 4 (3 to < 6 years)-and given weight-based doses of GLE and PIB for 8, 12, or 16 weeks. Primary endpoints were sustained virologic response at posttreatment week 12 (SVR12) and steady-state exposure; secondary endpoints were rates of persistent viremia, relapse, and reinfection. Safety and laboratory abnormalities were assessed. Final pediatric dosages determined to be efficacious were 250 mg GLE + 100 mg PIB (in children weighing ≥ 30 to < 45 kg), 200 mg GLE + 80 mg PIB (≥ 20 to < 30 kg), and 150 mg GLE + 60 mg PIB (12 to < 20 kg). Of 80 participants enrolled and dosed, 96% (77/80) achieved SVR12. One participant, on the initial dose ratio, relapsed by posttreatment week 4; no participants had virologic failures on the final dose ratio of GLE 50 mg/PIB 20 mg. Two nonresponders prematurely discontinued the study. Most adverse events (AEs) were mild; no drug-related serious AEs occurred. Pharmacokinetic exposures were comparable to those of adults.

CONCLUSIONS

A pediatric formulation of GLE/PIB was highly efficacious and well tolerated in chronic HCV-infected children 3 to < 12 years old.

Для цитирования: Jonas Maureen M, Rhee Susan, Kelly Deirdre A, Del Valle-Segarra Antonio, Feiterna-Sperling Cornelia, Gilmour Susan, Gonzalez-Peralta Regino P, Hierro Loreto, Leung Daniel H, Ling Simon C, Lobzin Yuri, Lobritto Steven, Mizuochi Tatsuki, Narkewicz Michael R, Sabharwal Vishakha, Wen Jessica, Kei Lon Hoi, Marcinak John, Topp Andrew, Tripathi Rakesh, Sokal Etienne. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study.. Hepatology (Baltimore, Md.). 2021. DOI: 10.1002/hep.31841.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.